Interstate Cannabis Commerce: How to Position for the Coming Trade Network

August 27, 2026

Photo via Pexels.

Every few months someone in this industry declares that interstate cannabis commerce is about to arrive, usually pegged to whatever federal headline just broke. It didn't happen when hemp was federally legalized. It didn't happen when the first states passed reciprocity language back in the early 2020s. And it isn't going to happen on a fixed date now, no matter how many press releases treat rescheduling as the starting gun. What changed this year is real, and it matters -- but it's a set of specific, documented legal and corporate moves, not a countdown clock.

This piece is about positioning, not prophecy. We're going to walk through exactly what the Trump administration's rescheduling order did and didn't do, what a Ninth Circuit panel just ruled about state licensing walls, which states are quietly pre-writing laws to activate the moment Washington moves, how one large California operator is already building for a national market that doesn't legally exist yet, and a hemp policy fight that could yank the rug out from under all of it. None of this tells you the month interstate trade opens. All of it tells you what a business can do right now, with the facts on the ground today, to not be caught flat-footed whenever it does.

What Actually Changed in 2026 -- and What Didn't

Photo by asteinfest via Pixabay.

Start with what's documented. On December 18, 2025, President Trump signed an executive order directing the Attorney General to expedite the long-stalled marijuana rescheduling process. Acting Attorney General Todd Blanche followed through on April 22, 2026, with a final order moving FDA-approved marijuana products and state-regulated medical marijuana products from Schedule I to Schedule III of the Controlled Substances Act. That's a genuine shift with real consequences: Schedule III status ends the application of Section 280E of the tax code to the products it covers, which has forced state-legal cannabis businesses to pay tax on gross profit rather than net income for years, and it opens doors for pharmaceutical-grade research and manufacturing that Schedule I effectively blocked.

Here's what it didn't do, and this is the part getting lost in a lot of trade-press coverage: Schedule III does not legalize interstate transport of cannabis. The carve-out in Blanche's order applies specifically to FDA-approved marijuana products and state-regulated medical marijuana -- adult-use and recreational product lines, which represent the bulk of the industry's revenue, remain outside that carve-out and federally restricted exactly as before. A grower in Oregon still cannot legally ship flower to a dispensary in Nevada because the DEA moved a substance from one schedule to another.

The more consequential admission, one that legal analysts have been unusually direct about, is that nobody actually knows how rescheduling interacts with Dormant Commerce Clause doctrine -- the constitutional principle that limits states from discriminating against interstate commerce absent a valid federal interest. This isn't a technicality waiting on some future court to rubber-stamp. It's an open, contested question. Does a substance's move to Schedule III change how courts evaluate state residency requirements or in-state-only licensing schemes? Does it strengthen the argument that Congress no longer intends to keep cannabis markets siloed by state, or does it change nothing because the interstate transport of federally controlled substances still requires separate authorization under federal law and DEA registration rules?

The cleanest way to hold these two facts in your head at once: Schedule III is an administrative action taken by the DEA under authority delegated by Congress. Interstate commerce is a separate constitutional and statutory question, resting on Commerce Clause doctrine and on whatever Congress does or doesn't do next. Rescheduling changed the tax and research landscape substantially. It left the interstate commerce question exactly where it was -- unresolved, and now the subject of active litigation.

The Ninth Circuit Just Drew a Line Across the Map

Photo by OpenRoadPR via Pixabay.

That litigation produced its first real answer on January 2, 2026, when a three-judge panel of the Ninth Circuit Court of Appeals ruled unanimously in Peridot Tree WA, Inc. v. Washington State Liquor & Cannabis Control Board, 162 F.4th 1179. The plaintiffs argued that Washington's residency requirements for cannabis licenses violated the Dormant Commerce Clause by discriminating against out-of-state economic interests. Judge Daniel Bress, writing for the panel, rejected that argument on a specific and carefully reasoned basis: the Dormant Commerce Clause exists to protect a national marketplace that Congress wants to function without state-by-state discrimination, and Congress has explicitly deemed the marijuana marketplace illegal under federal law. You cannot invoke a constitutional doctrine meant to protect interstate commerce, Bress reasoned, to force open a commerce channel that federal statute still closes. Courts applying the Dormant Commerce Clause to strike down state cannabis restrictions, in his framing, would be facilitating the exact national marketplace Congress has disallowed -- an outcome the judiciary has no business engineering on its own.

The practical map this creates is uneven, and that unevenness is the point. Within the Ninth Circuit's footprint -- California, Washington, Oregon, Nevada, Arizona, and several other western and Pacific states -- residency preferences and in-state-only licensing restrictions are now insulated from constitutional challenge, at least for now. That's a meaningfully different legal environment than in the First or Second Circuits, where similar residency and in-state restrictions haven't been tested under this reasoning and remain vulnerable to Dormant Commerce Clause challenges. A cannabis company evaluating where to headquarter multi-state ambitions is looking at two different bodies of applicable law depending on which side of a circuit boundary it sits.

None of this is final. Appellants in Peridot Tree had until March 17, 2026 to petition for en banc rehearing before the full Ninth Circuit, and given that this ruling sits in tension with how other circuits are likely to treat the same question, this is exactly the kind of circuit split that eventually draws Supreme Court review. That could take years to develop and resolve.

For operators, the lesson is straightforward: the legal environment for interstate positioning is going to be regional and inconsistent for the foreseeable future, not a single national switch that flips on one date. Site selection, licensing strategy, and partnership structures need to account for which circuit you're operating in, not just which state.

Trigger Laws: States Are Pre-Loading the Infrastructure

While courts work through the constitutional questions, a handful of state legislatures have been doing something quieter and, in a way, more telling: writing laws that do nothing until Washington acts, then do everything the instant it does. In June 2026, Vermont Governor Phil Scott signed a bill authorizing the governor to enter into interstate cannabis commerce agreements with other states -- but only once one of three specific federal triggers occurs: a change in federal law rescheduling or descheduling cannabis, an act of Congress barring federal prosecution of interstate cannabis transfers, or a formal federal opinion tolerating such commerce. Until one of those three things happens, the Vermont law is inert. It's a piece of pre-loaded infrastructure sitting on a shelf.

This isn't a new idea -- Vermont copied it almost directly from California, which passed a similar trigger-clause structure under SB 1326. The language is nearly identical: a conditional authorization that activates automatically once a named federal event occurs, without requiring the legislature to reconvene and debate the question under time pressure.

The pattern is worth naming because it isn't unique to cannabis. States have used the same trigger-law playbook before, in early medical marijuana reciprocity compacts that recognized other states' patient cards contingent on matching regulatory standards, and in interstate compacts governing water rights and gambling that only took legal effect once a defined external condition was met -- often a federal approval, an interstate agreement ratified by Congress, or a court ruling. The logic is consistent across all of these: legislatures write and pass the law during the waiting period, so that once the federal blocker lifts, implementation is immediate rather than dependent on a fresh legislative session that could get delayed, amended, or politically stalled.

What this means practically is that trigger-law adoption is a signal worth tracking on its own merits, independent of when or whether the federal trigger actually fires. A state passing Vermont- or California-style compact language is telling you, in concrete legislative terms, that its policymakers expect to participate in interstate cannabis trade and want to be ready for it. Watch for more large-canopy western states -- plausibly Oregon, Washington, or Colorado -- to adopt similar statutes over the next one to three years. It costs those states nothing today and positions them to move first tomorrow.

Glass House and the Multi-State Operator Playbook

Photo by CRYSTALWEED cannabis via Unsplash.

If trigger laws are the legislative version of pre-positioning, Glass House Group is the corporate version, and it's worth looking at closely because other large operators are likely to copy pieces of it. Glass House operates more than 6 million square feet of production capacity in California and is projecting roughly 1 million pounds of cannabis biomass produced in 2026 -- a scale that puts it among the largest cultivators in the country, let alone the state.

On June 30, 2026, the company converted its operations to medical-only status and uplisted to a major national stock exchange. That's a deliberate, expensive bet: a national exchange listing requires audited financials, SEC-level disclosure, and governance standards that go well beyond what a state-licensed cannabis company typically maintains. Glass House is choosing to absorb that cost now, ahead of any interstate transport authorization, because federal-grade legitimacy -- a national exchange listing, audited books, a governance structure that satisfies institutional investors -- is exactly the kind of infrastructure that becomes valuable the moment interstate commerce becomes legally possible and buyers, banks, and regulators need to assess who's trustworthy enough to move product across state lines.

The company has also pursued DEA registration on two separate tracks simultaneously: one as a medical cannabis company qualifying under the April 2026 rescheduling order's carve-out, and a second, separate track as a bulk exporter and manufacturer. That second track matters because it isn't really about serving today's California medical market -- it's compliance infrastructure built for a national and potentially international export role that doesn't exist yet under current law, but that the company is positioning to step into immediately if and when it does.

Company president Graham Farrar has framed the strategy plainly: what's left, in his telling, is a green light from the states. Whether or not that's precisely accurate as a legal matter -- given the unresolved commerce clause questions the Ninth Circuit just waded into -- it captures the operator logic clearly. Build scale and federal-grade compliance during the waiting period, rather than scrambling to build it after the gate opens and competitors have a head start.

This is a template other large-canopy operators -- cultivators in Ohio, Michigan, Oklahoma, states that have built out substantial licensed production capacity -- could plausibly copy: over-build capacity, pursue whatever federal registration status is currently available, and bet on being first movers once transport restrictions lift. It's a capital-intensive strategy that assumes the wait is finite and worth the carrying cost. Not every operator can afford that assumption.

The Hemp Wildcard That Could Complicate Everything

Photo via Pexels.

Just as marijuana interstate commerce inches forward, a completely separate fight over hemp-derived cannabinoids could undercut the one commerce channel that's actually working today. Section 781 of the 2026 Appropriations Act, as currently drafted, would render an estimated 95% of hemp-derived cannabinoid products -- delta-8 THC gummies, THC seltzers and beverages, and similar consumer products that have built a multi-billion-dollar retail category since hemp's federal legalization -- federally unlawful by November 12, 2026. That's not a hypothetical distant deadline; it's a specific date attached to specific legislative text moving through Congress right now.

Competing legislation offers a very different path. The Cannabinoid Safety and Regulation Act, H.R. 3474, would instead expressly authorize interstate hemp commerce while giving individual states the ability to opt out if they choose stricter local rules. It's the mirror image of Section 781: instead of federal restriction by default, it's federal authorization by default with a state opt-out valve.

Why this matters for the marijuana interstate-commerce conversation specifically: hemp-derived products already move across state lines legally today, protected by the federal definition of hemp based on its low delta-9 THC content by dry weight. It's the one cannabinoid category that has functioning, federally sanctioned interstate commerce right now. If Section 781 passes as written, that category gets largely eliminated right as the marijuana side of the industry is trying to build the case that interstate cannabinoid commerce can work responsibly. Losing the working example while making the case for the untested one is an awkward position for the industry to be in.

The split between these two bills is also a preview of the exact fight likely to recur over marijuana once rescheduling's silence on commerce gets addressed by Congress directly: a safety- and control-focused federal restriction model versus a state-opt-out commerce model that trusts states to regulate within a federal floor. Which philosophy wins the hemp fight will likely shape the template used for the marijuana fight that follows it.

None of this is settled. The November 12, 2026 deadline in Section 781 is real and concrete. Which bill, if either, ultimately prevails -- whether Congress lets the restrictive provision take effect, passes the opt-out model instead, or produces some hybrid compromise -- is genuinely unresolved as of this writing, and businesses should treat it as an open legislative fight rather than a foregone conclusion in either direction.

Positioning Now: What Businesses Can Actually Do Before the Gate Opens

Photo by BulentYILDIZ via Pixabay.

Given all of that, what can a business actually do before any gate opens? A few concrete moves stand out, each grounded in what's documented above rather than in guesswork about timing.

First, build compliance infrastructure that would survive under multiple regulatory regimes at once -- state, and eventually federal. That means track-and-trace systems robust enough to satisfy not just your home state's seed-to-sale requirements but a hypothetical federal oversight body; lab testing accreditation that meets the strictest state standard you operate under, not the loosest; and financial audit trails clean enough to survive the kind of scrutiny Glass House now lives under as a listed company. This infrastructure has value today, in the state markets you're already in, and it's the same infrastructure that positions you for interstate trade later.

Second, treat jurisdiction as a strategic variable, not just a licensing formality. Given the Peridot Tree ruling, Ninth Circuit states currently offer more legal certainty for residency-based or in-state licensing structures than First or Second Circuit states do. That's a real, current difference that should factor into where you base cultivation versus where you base retail or distribution operations, at least until the circuit split resolves one way or another.

Third, watch trigger-law adoption as a leading indicator, the way you'd watch a permitting pipeline. A state passing Vermont- or California-style compact legislation is telling you directly that its policymakers expect to be ready to participate in interstate trade. That's useful, concrete information for site selection and partnership decisions, independent of when the federal trigger actually fires.

Fourth, consider a national stock exchange listing or uplisting as one path to capital access -- but go in with eyes open about the conservative counter-case. Major exchange listing standards, along with SEC disclosure obligations, raise real costs: audited financials, governance overhead, compliance staffing that a company doing a few million pounds a year can absorb and a smaller regional operator likely can't. This route currently favors large-canopy incumbents like Glass House, not the mid-size operators who make up most of the industry.

And finally, hold the timing loosely. Some legal analysts point out, reasonably, that the Ninth Circuit ruling and rescheduling's silence on interstate commerce could just as easily push a resolution years further out if the developing circuit split reaches the Supreme Court and produces a ruling unfavorable to interstate trade. Positioning for a fast resolution is one bet. Positioning for a long, uneven, regionally fragmented wait is the more conservative one -- and given the facts on the ground, it's currently the better-supported bet.

It's tempting to read the rescheduling order, the Glass House playbook, and the trigger laws as three pieces of the same inevitable story converging on an open interstate market. Maybe they are. But Section 781 is sitting right there as a reminder that Congress can tighten cannabinoid commerce just as easily as it loosens it -- and with a specific November 12, 2026 deadline, it's doing exactly that to hemp products right now, in the same legislative session that produced the rescheduling order everyone's celebrating.

A business that's built its entire multi-year strategy on the assumption that federal cannabis policy only moves in one direction is making a bet the historical record doesn't fully support. The prudent version of this strategy hedges both ways: build the compliance and capacity infrastructure that pays off if interstate marijuana trade opens on a three-to-seven-year horizon, but don't structure your balance sheet so that a hemp-style rollback, or a Supreme Court ruling that goes the wrong way on the circuit split, takes the whole plan down with it. The gate might open. Congress has also just shown, in real time, that it's equally capable of welding one shut.